ArticleCureus2025
Real-World Efficacy of Upadacitinib in Patients With Ulcerative Colitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- A Comparison of the Efficacy and Safety of Ustekinumab and Upadacitinib in Biologically Experienced Ulcerative Colitis Patients.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upadacitinib (UPA) is a selective JAK-1 inhibitor used in the treatment of ulcerative colitis (UC) and Crohn's disease. We report a real-world retrospective study evaluating the efficacy and safety of UPA in 17 patients who scaled from mild to severe UC, and demonstrated significant improvement in Inflammatory biomarkers, with the majority (16/17 patients) achieving reduced fecal calprotectin levels. Three patients had subsequent endoscopic evaluation after being initiated on UPA; two showed improvement in the Mayo score, and the remaining patient remained static. The side effect profile was consistent with known JAK inhibitor effects, with elevated cholesterol as the most common adverse event, and one case of neutropenia was observed. These findings suggest that UPA is an effective therapeutic option for refractory UC patients, and further studies would help in confirming its long-term efficacy in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.